A Pakistani patient battling highly complex advanced ovarian cancer has received comprehensive treatment at Fudan University Shanghai Cancer Center, marking another milestone showcasing the global impact of China’s standardized ovarian cancer management protocols.
The patient suffered extensive tumor invasion across multiple abdominal organs and showed poor response to conventional neoadjuvant chemotherapy locally last year. With nearly no viable surgical options available at home, she traveled thousands of miles to Shanghai seeking multidisciplinary advanced care.
Led by Dr Wu Xiaohua, the hospital’s gynecologic oncology MDT team carried out rigorous preoperative assessment and performed radical tumor resection via multi-organ combined surgery. The procedure preserved key organ functions and helped improve the patient’s quality of life.
Following postoperative chemotherapy and maintenance therapy, the patient recovered steadily. After returning to Pakistan, she continued to receive remote treatment guidance from Wu’s team.
Recent routine surveillance detected early signs of tumor recurrence through high-precision PET-CT scans and tumor biomarker tests. She flew back to Shanghai in late July for reassessment and subsequent treatment planning.
Considering the patient’s genetic and pathological profiles, the team launched individualized targeted ADC therapy. The center hosts a range of pioneering clinical trials on ADC agents.
To date, the patient has completed her first cycle of ADC treatment and is set to return home.
“We are grateful to receive such personalized targeted therapy in China and plan to come back to Shanghai regularly for follow-up evaluations,” the patient’s family stated.
“Adopting a full-cycle management framework spanning surgery, chemotherapy, maintenance therapy and targeted treatment, we aim to help more advanced ovarian cancer patients like her. We hope to share our experience to advance global cancer prevention and treatment,” said Dr Wu Xiaohua.
Fudan University Shanghai Cancer Center manages one of the largest ovarian cancer patient cohorts nationwide. In 2025, the hospital conducted more than 2,285 ovarian cancer surgeries, accounting for over 40 percent of all such procedures in Shanghai. Drawing on its extensive clinical database, Wu’s team has developed an innovative surgical management system. The initiative lifted the R0 resection rate for newly diagnosed ovarian cancer from 31 percent to 77.8 percent, substantially boosting patients’ quality of life and pushing the five-year survival rate above 50 percent.
“Even for intermediate and advanced ovarian cancer, precise evaluation paired with customized treatment regimens can greatly raise the chance of curative R0 resection. As oncology enters the precision medicine era, ongoing clinical trials create new opportunities for full-cycle patient management and longer survival,” Wu noted.
Backed by profound clinical expertise and persistent research, the hospital's department of gynecologic oncology spearheads multiple domestic and international clinical trials. These efforts raise the global profile of China’s homegrown anti-cancer therapies and draw numerous international patients seeking cross-border medical services.
“This trust that crosses national borders represents the highest recognition of our work, and drives us to strive for continuous breakthroughs,” Wu added.
